Physician profile
Mark Eric Hessenthaler
NPI 1487776506
$4,546.99
in general payments reported to CMS, 2019-2025
21 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $171 · 2021: $323 · 2022: $578 · 2023: $2,100 · 2024: $318 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015 · Travel and Lodging: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.15 |
| Travel and Lodging | $929.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,594.45 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $415.19 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.42 | 2019-2023 | Trintellix |
| Lundbeck LLC | $259.48 | 2019-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $245.17 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Vanda Pharmaceuticals INC. | $243.80 | 2020-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.17 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $181.10 | 2019-2025 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $154.11 | 2019 | |
| Alkermes, INC. | $132.91 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $131.28 | 2019-2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $115.85 | 2020-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $104.22 | 2022-2024 | |
| Axsome Therapeutics, INC. | $102.75 | 2024-2025 | Auvelity |
| Shire North American Group INC | $87.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $78.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $53.53 | 2025 | Cobenfy |
| Corium, LLC | $46.38 | 2022 | |
| Allergan, INC. | $31.57 | 2020 | |
| Bausch Health US, LLC | $31.49 | 2019-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $23.11 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hessenthaler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.